Danish vaccine maker Bavarian Nordic (OMX: BAVA) has signed a licensing and manufacturing agreement with the Serum Institute of India (SII) to expand production capacity for its mpox vaccine Jynneos.
The agreement, which follows a profit-sharing model with no upfront or milestone payments, will allow SII to produce and distribute the vaccine in India while boosting global manufacturing capacity.
Under the deal, the companies will conduct a technology transfer for the vaccine's manufacturing process. SII is responsible for securing and maintaining regulatory approvals in India, with both parties covering their respective costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze